文献速递肾小球疾病慢性肾脏病

SGLT2抑制剂在非糖尿病肾小球疾病中的降蛋白尿效应取决于体重指数

Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

这项回顾性、多中心、国际观察性队列研究纳入300例经活检证实、蛋白尿>0.5 g/24 h且接受SGLT2抑制剂的非糖尿病肾小球疾病患者,评估体重指数对降蛋白尿疗效的影响。结果显示,超重和肥胖患者启动SGLT2抑制剂后蛋白尿显著下降(P<.001 vs 0.18),而体重指数正常患者未见预期早期eGFR下降(P=.16)。结论认为SGLT2抑制剂在体重指数<25 kg/m2患者中降蛋白尿无效。

要点

  • 超重和肥胖的非糖尿病肾小球疾病患者启动SGLT2抑制剂后蛋白尿显著下降。
  • 体重指数正常(<25 kg/m2)患者未见蛋白尿显著下降。
  • 体重指数正常患者未出现预期的早期eGFR下降(P=.16)。

核心结论

  • SGLT2抑制剂在体重指数<25 kg/m2的非糖尿病肾小球疾病患者中降蛋白尿无效,与超重和肥胖患者蛋白尿显著下降形成对比。

研究设计与样本

  • 回顾性、多中心、国际观察性队列研究,纳入2016年至2023年间接受SGLT2抑制剂的非糖尿病、经活检证实肾小球疾病且蛋白尿>0.5 g/24 h的患者,共300例符合纳入标准。
  • 在基线及3-6个月后获取蛋白尿和估算肾小球滤过率等实验室值,采用配对符号秩检验分析随时间的变化。

主要发现

  • 中位年龄51.82岁(IQR 41-62.65),男性占64.7%,白人占92.7%,最常见肾小球疾病为免疫球蛋白A肾病(40.3%)。
  • 中位eGFR为52.26 ml/min/1.73 m2(IQR 36.41-74.01),中位蛋白尿为1.60 g/24 h(IQR 1.15-2.91),中位血清白蛋白为4.08 g/dl(IQR 3.80-4.30)。
  • 启动SGLT2抑制剂后蛋白尿下降仅在超重和肥胖患者中显著(P<.001 vs 0.18)。
  • 体重指数正常患者未出现预期的早期eGFR下降(P=.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are emerging as an essential part of the standard of care for proteinuria in patients with chronic kidney disease. To date, no study has specifically evaluated the effects of body mass index (BMI) on the antiproteinuric efficacy of SGLT2is. Here we report the impact of BMI on the antiproteinuric efficacy of SGLT2is in non-diabetic patients with glomerular diseases. METHODS: This is a retrospective, multicentre, international observational cohort study that included non-diabetic patients with biopsy-proven glomerular disease and proteinuria >0.5 g/24 h who received SGLT2is between 2016 and 2023. Laboratory values, including proteinuria and estimated glomerular filtration rate (eGFR), were obtained at baseline and after 3-6 months. Changes in laboratory values over time were analysed using the paired signed-rank test. RESULTS: A total of 300 patients met the inclusion criteria. The median age was 51.82 years [interquartile range (IQR) 41-62.65], 64.7% were male and 92.7% were white. The most common glomerular disease was immunoglobulin A nephropathy (40.3%). The median eGFR was 52.26 ml/min/1.73 m2 (IQR 36.41-74.01), the median proteinuria was 1.60 g/24 h (IQR 1.15-2.91) and the median serum albumin was 4.08 g/dl (IQR 3.80-4.30). Proteinuria reduction after SGLT2i initiation was significant only in overweight and obese patients (P < .001 versus 0.18). Patients with normal BMI did not experience the expected early decrease in eGFR (P = .16). CONCLUSIONS: SGLT2is are ineffective in proteinuria reduction in patients with a BMI <25 kg/m2, which contrasts with the significant proteinuria reduction in overweight and obese patients with glomerulopathies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Vargas-Brochero MJ, Russo I, Mazzierli T, et al. Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index. Nephrol Dial Transplant. 2026. PMID: 40996459. doi:10.1093/ndt/gfaf197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。